Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

Pfizer has appointed Jeffrey Legos, PhD, MBA, as its new Chief Oncology Officer1 9.

Dr. Legos joins Pfizer from Novartis, where he served as Executive Vice President and Global Head of Oncology and Hematology Development1 2.

In his new role, Dr. Legos will lead Pfizer's Oncology Research & Development, overseeing functions from pre-clinical to late-stage clinical development activities1.

Dr. Legos has over 20 years of experience in oncology drug development, contributing to more than 40 global regulatory drug and companion diagnostic approvals1 2.

This appointment is part of Pfizer's strategy to strengthen its oncology portfolio following the $43 billion acquisition of Seagen in 20233 5.

Pfizer aims to have at least eight blockbuster cancer drugs by 2030, focusing on breast cancer, genitourinary cancer, blood cancer, and thoracic cancers5 8.

Dr. Legos will report to Chris Boshoff, Chief Scientific Officer and President of Pfizer Research & Development1.

This leadership change comes as Pfizer faces challenges with declining COVID-19 vaccine sales and upcoming patent expirations for key drugs3.

Pfizer is counting on its expanded oncology division to boost sales and regain investor confidence in the coming years3 5.

Dr. Legos replaces interim chief oncology officer Roger Dansey, who will transition to retirement1 3.